OM Healthcare Logistics lands first major customer: CareFusion
New 3PL will add a second facility by year-end; stresses the economies of consolidated shipping
Having opened its doors less than 12 months ago, OM Healthcare Logistics has signed a five-year deal with CareFusion (San Diego), the spinout from Cardinal Health that is also about a year old. OM Healthcare Logistics (OMHL), a business unit of the major medical-device wholesaler Owens & Minor (Richmond, VA), will open a new facility by year-end in Redlands, CA, to handle the new business; combined with the facility in Lexington, KY, the unit will have warehouse capacity of 475,000 sq. ft.
“Becoming the logistics provider for CareFusion is an important step in our efforts to provide the healthcare supply chain with innovative solutions and new logistics efficiencies,” says Craig Smith, president and CEO of O&M. Douglas Witter, VP of sales and marketing at OMHL, says that the company is stressing the economies of consolidated shipping—combining shipments of multiple manufacturers or orders to delivery points. “We can take parcels and make them less-than-truckload (LTL) shipments, and take LTL shipments and make them truckload deliveries,” he says. “The savings in transportation costs can approach 20-40%.”
The OMHL facilities are cGMP-compliant, and the company is registered as a controlled-substances distributor with DEA, as well as a relabeler with FDA. “These capabilities will allow us to perform kitting services in addition to basic warehousing and transportation,” says Witter.
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
